Business
NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., May 12, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology
About this update from Neuroone Medical Technologies Corporation
[{"type":"text","content":"EDEN PRAIRIE, Minn., May 12, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (\"NeuroOne\" or the \"Company\"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter of fiscal year 2022 ended March 31, 2022.\n\n \n \n \n \n \n \n\n \nSecond Quarter and Recent Business UpdatesEvo® sEEG electrode first commercial order is in inventory and ready to ship pending FDA clearance for less than 30 day duration of use. The Evo sEEG electrode was already 510(k) cleared for temporary (less than 24 hours) use.Filed appeal with the FDA regarding their decision related to the Company's request for clearance for less than 30 day use of NeuroOne's Evo® sEEG Electrode. Appeal meeting between NeuroOne and the FDA was held on April 14th, 2022.Participated in Zimmer Biomet's physician advisory board meeting with prominent neurosurgeons to perform usability testing of Evo sEEG implant accessories.Initiated the process to qualify a second source to manufacture electrodes for Evo® Cortical and sEEG product lines to increase manufacturing capacity and reduce supply risk for both product lines.Initiated cost reduction program for cable assembly.Exhibited our Evo Cortical electrode product family at the University of Minnesota Neuromodulation Symposium and presented at the Gordon Research Conference 2022 Neuroelectronic Interfaces Meeting.Announced positive five-year bench top results in stimulation testing of electrodes designed for use in spinal cord stimulation for patients suffering with chronic back pain.Completed prototypes for RF ablation system as well as planning phase with our hardware partner RBC Medical Systems which remains on schedule to submit to FDA in the first quarter of calendar year 2023 for commercial clearance.Appointed Maria Vomero, PhD., a prominent scientist and expert in thin film electrode technology to drive the Company's spinal cord stimulation program, further strengthening the development team.NeuroOne featured on \"The Claman Countdown,\" an American financial program airing on the Fox Business Network.Presented at the 34th Annual Roth Capital Partners Conference and the Oppenheimer 32nd Annual Virtual Healthcare Conference.Dave Rosa, CEO of NeuroOne co...